Huntington National Bank lessened its holdings in Cooper Companies Inc (NYSE:COO) by 4.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,264 shares of the medical device company’s stock after selling 439 shares during the quarter. Huntington National Bank’s holdings in Cooper Companies were worth $2,751,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. Flagship Harbor Advisors LLC grew its holdings in shares of Cooper Companies by 62.5% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 78 shares of the medical device company’s stock worth $26,000 after purchasing an additional 30 shares during the last quarter. World Asset Management Inc lifted its position in Cooper Companies by 1.2% during the 2nd quarter. World Asset Management Inc now owns 2,744 shares of the medical device company’s stock worth $924,000 after buying an additional 32 shares in the last quarter. Signaturefd LLC lifted its position in Cooper Companies by 3.8% during the 2nd quarter. Signaturefd LLC now owns 875 shares of the medical device company’s stock worth $295,000 after buying an additional 32 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Cooper Companies by 0.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,282 shares of the medical device company’s stock worth $3,464,000 after buying an additional 38 shares in the last quarter. Finally, Advisory Services Network LLC lifted its position in Cooper Companies by 13.6% during the 2nd quarter. Advisory Services Network LLC now owns 318 shares of the medical device company’s stock worth $107,000 after buying an additional 38 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts recently issued reports on COO shares. Piper Jaffray Companies set a $360.00 price target on shares of Cooper Companies and gave the stock a “buy” rating in a research report on Friday, August 30th. ValuEngine downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. KeyCorp reduced their price target on shares of Cooper Companies from $351.00 to $348.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Wells Fargo & Co upped their target price on shares of Cooper Companies from $356.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Finally, Raymond James restated a “buy” rating on shares of Cooper Companies in a research report on Monday, August 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. Cooper Companies presently has a consensus rating of “Buy” and a consensus target price of $326.00.
Shares of NYSE:COO traded down $3.80 during mid-day trading on Friday, reaching $290.95. The stock had a trading volume of 6,159 shares, compared to its average volume of 262,663. The firm has a market cap of $14.42 billion, a PE ratio of 25.30, a price-to-earnings-growth ratio of 2.14 and a beta of 0.90. The firm has a 50 day simple moving average of $292.41 and a two-hundred day simple moving average of $309.62. The company has a current ratio of 1.29, a quick ratio of 0.73 and a debt-to-equity ratio of 0.39. Cooper Companies Inc has a twelve month low of $228.65 and a twelve month high of $344.32.
Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, August 29th. The medical device company reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.16 by $0.07. The business had revenue of $679.40 million for the quarter, compared to the consensus estimate of $687.60 million. Cooper Companies had a net margin of 17.08% and a return on equity of 17.15%. Cooper Companies’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the company posted $3.00 EPS. On average, equities analysts anticipate that Cooper Companies Inc will post 12.32 EPS for the current fiscal year.
In related news, Director Allan E. Rubenstein sold 1,335 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $299.61, for a total value of $399,979.35. Following the sale, the director now directly owns 3,591 shares in the company, valued at approximately $1,075,899.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.70% of the company’s stock.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Story: What is a Tariff?
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.